Serrano, who spoke to reporters in a briefing ahead of his study's publication in the journal Nature on Wednesday, said one of his most striking findings was that the iPS cells generated in the living mice seem to be more similar to embryonic stem cells than to iPS cells created in petri dishes.
Specifically, he said, the iPS cells reprogrammed in living mice showed the potential to differentiate into more cell types than standard iPS cells or embryonic stem cells - suggesting that reprogramming cells in a living mammal produces cells with greater potential, or what scientists call more plasticity.
Chris Mason, a professor of regenerative medicine at University College London, said he had no doubt that being able to reprogram cells in the body to different cell types would be useful in producing future therapies capable of transforming patients' lives, but said there were many more years of research ahead before that would be possible.
"The cells that will be useful will not be the pluripotent stem cells (iPS cells), but their more specialized ('adult') offspring," he said.
"This.. is an interesting proof of concept of the first step in the process, but it still needs these iPS cells to be safely converted to useful 'adult' cell types in the body."
He said the major challenge in this potential approach to treating patients in the future would be tightly controlling every step of the process to make sure it delivered benefits while also avoiding complications.
(Reporting by Kate Kelland, editing by Ralph Boulton)
- Link this
- Share this
- Digg this
- Email
- Reprints
0 comments:
Post a Comment